Literature DB >> 11830490

Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2.

Stefan Joos1, Christiane K Menz, Gunnar Wrobel, Reiner Siebert, Stefan Gesk, Sibylle Ohl, Gunhild Mechtersheimer, Lorenz Trümper, Peter Möller, Peter Lichter, Thomas F E Barth.   

Abstract

Hodgkin- and Reed-Sternberg (HRS) cells microdissected from 41 classical Hodgkin lymphomas (cHL) of 40 patients comprising 8 lymphocyte-rich (cHL-LR), 16 nodular sclerosis (cHL-NS), 15 mixed-cellularity (cHL-MC), and 2 lymphocyte-depletion (cHL-LD) subtypes were analyzed by comparative genomic hybridization for recurrently imbalanced chromosomal subregions. Chromosomal gains most frequently involved chromosome 2p (54%), 12q (37%), 17p (27%), 9p and 16p (24% each), and 17q and 20q (20% each), whereas losses primarily affected chromosome 13q (22%). Using fluorescence in situ hybridization, amplification of the REL oncogene was demonstrated within a distinct 2p15-p16 amplicon. The high frequency of 2p overrepresentations including REL, particularly in cHL-NS (88%), suggests that an alternative mechanism of constitutive activation of nuclear factor NF-kappaB is a hallmark of HRS cells. Hierarchical cluster analysis of chromosomal imbalances revealed a closer relationship among cHL-NS than other subtypes. Furthermore, there is a tendency for different subtypes of cHL-MC tumors characterized by different ages at the time of tumor onset and gain of chromosome 17p. The imbalance pattern of cHL subtypes suggests that different molecular pathways are activated, with REL or other genes on chromosomal band 2p15-p16 playing a fundamental role in the pathogenesis of classical Hodgkin lymphoma.

Entities:  

Mesh:

Year:  2002        PMID: 11830490     DOI: 10.1182/blood.v99.4.1381

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma.

Authors:  Sabine Franke; Iwona Wlodarska; Brigitte Maes; Peter Vandenberghe; Ruth Achten; Anne Hagemeijer; Chris De Wolf-Peeters
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma.

Authors:  Ewerton M Maggio; Anke Van Den Berg; Debora de Jong; Arjan Diepstra; Sibrand Poppema
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

3.  Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.

Authors:  Björn Lamprecht; Korden Walter; Stephan Kreher; Raman Kumar; Michael Hummel; Dido Lenze; Karl Köchert; Mohamed Amine Bouhlel; Julia Richter; Eric Soler; Ralph Stadhouders; Korinna Jöhrens; Kathrin D Wurster; David F Callen; Michael F Harte; Maciej Giefing; Rachael Barlow; Harald Stein; Ioannis Anagnostopoulos; Martin Janz; Peter N Cockerill; Reiner Siebert; Bernd Dörken; Constanze Bonifer; Stephan Mathas
Journal:  Nat Med       Date:  2010-05-02       Impact factor: 53.440

Review 4.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

5.  Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.

Authors:  Christoph Renné; Jose Ignacio Martin-Subero; Maren Eickernjäger; Martin-Leo Hansmann; Ralf Küppers; Reiner Siebert; Andreas Bräuninger
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 6.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

Review 7.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

8.  A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.

Authors:  Wei Wei; Yuquan Lin; Zhihui Song; Wenming Xiao; Liqi Chen; Jiejing Yin; Yan Zhou; Stefan K Barta; Michael Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

Review 9.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

10.  Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.

Authors:  Stephen J Salipante; Andrew Adey; Anju Thomas; Choli Lee; Yajuan J Liu; Akash Kumar; Alexandra P Lewis; David Wu; Jonathan R Fromm; Jay Shendure
Journal:  Genes Chromosomes Cancer       Date:  2015-12-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.